Skip to main content
SpringerLink
Log in

Melanoma Epidemiology, Staging and Prognostic Factors

  • Chapter
  • First Online:
Practical Manual for Dermatologic and Surgical Melanoma Management

  • 438 Accesses

Abstract

Melanoma is one of the most feared human malignancies because of its metastatic potential. However, most melanomas are fully cured by surgical removal and only a minority of patients diagnosed with melanoma will succumb to the disease. To care for our patients with this potentially deadly disease, it is essential to understand the metastatic and mortality risk of the disease. Staging has been developed to categorize patients and create groups who are expected to have similar clinical outcomes. Staging uses the best prognostic markers, but staging does not provide precise individual assessment of likely outcome. Numerous prognostic factors exist beyond the staging criteria, which may also help predict distant metastasis and mortality risk. In this chapter we will review the staging and prognostic factors of melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Surveillance E, End Results (SEER) Program. Cancer stat facts: melanoma of the skin. Surveillance, epidemiology, and end results (SEER) program. 2019.

    Google Scholar 

  2. Gershenwald JE, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472–92. https://doi.org/10.3322/caac.21409.

    Article  PubMed  PubMed Central  Google Scholar 

  3. American Cancer Society. Cancer facts & figures 2019. 29 Apr 2019.

    Google Scholar 

  4. Gershenwald JE, Scolyer RA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann Surg Oncol. 2018;25:2105–10. https://doi.org/10.1245/s10434-018-6513-7.

    Article  PubMed  Google Scholar 

  5. Gershenwald JE, Scolyer R, Hess KR, et al. Melanoma of the skin. In: Edge SB, Amin MB, Greene FL, et al., editors. AJCC cancer staging manual. 8th ed. New York: Springer International Publishing; 2017. p. 563–85.

    Chapter  Google Scholar 

  6. Balch CM, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206. https://doi.org/10.1200/JCO.2009.23.4799.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29:705–27.

    PubMed  Google Scholar 

  8. Marghoob AA, Koenig K, Bittencourt FV, Kopf AW, Bart RS. Breslow thickness and Clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging. Cancer. 2000;88:589–95.

    Article  CAS  Google Scholar 

  9. Balch CM, et al. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark’s and Breslow’s staging methods. Ann Surg. 1978;188:732–42. https://doi.org/10.1097/00000658-197812000-00004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Cherobin ACFP, Wainstein AJA, Colosimo EA, Goulart EMA, Bittencourt FV. Prognostic factors for metastasis in cutaneous melanoma. An Bras Dermatol. 2018;93:19–26. https://doi.org/10.1590/abd1806-4841.20184779.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Stucky CC, et al. Risk factors associated with local and in-transit recurrence of cutaneous melanoma. Am J Surg. 2010;200:770–4; discussion 774–775. https://doi.org/10.1016/j.amjsurg.2010.07.025.

    Article  PubMed  Google Scholar 

  12. Faries MB, Wanek LA, Elashoff D, Wright BE, Morton DL. Predictors of occult nodal metastasis in patients with thin melanoma. Arch Surg. 2010;145:137–42. https://doi.org/10.1001/archsurg.2009.271.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Buttner P, et al. Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark’s level for prognostic classification. Cancer. 1995;75:2499–506.

    Article  CAS  Google Scholar 

  14. Balch CM, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622–34. https://doi.org/10.1200/jco.2001.19.16.3622.

    Article  CAS  PubMed  Google Scholar 

  15. Ellis R, et al. Epidermal AMBRA1 and Loricrin; a paradigm shift in the prognostication and stratification of AJCC stage I melanomas. Br J Dermatol. 2019. https://doi.org/10.1111/bjd.18086.

  16. Gimotty PA, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol. 2004;22:3668–76. https://doi.org/10.1200/jco.2004.12.015.

    Article  PubMed  Google Scholar 

  17. Baum C, et al. Sentinel node metastasis mitotic rate (SN-MMR) as a prognostic indicator of rapidly progressing disease in patients with sentinel node-positive melanomas. Int J Cancer. 2017;140:1907–17. https://doi.org/10.1002/ijc.30563.

    Article  CAS  PubMed  Google Scholar 

  18. Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer. 1996;78:427–32. https://doi.org/10.1002/(SICI)1097-0142(19960801)78:3<427::AID-CNCR8>3.0.CO;2-G.

    Article  CAS  PubMed  Google Scholar 

  19. Kunte C, et al. Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma. Melanoma Res. 2010;20:330–7. https://doi.org/10.1097/CMR.0b013e32833ba9ff.

    Article  PubMed  Google Scholar 

  20. Lattanzi M, et al. Primary melanoma histologic subtype: impact on survival and response to therapy. J Natl Cancer Inst. 2019;111:180–8. https://doi.org/10.1093/jnci/djy086.

    Article  CAS  PubMed  Google Scholar 

  21. Chen LL, Jaimes N, Barker CA, Busam KJ, Marghoob AA. Desmoplastic melanoma: a review. J Am Acad Dermatol. 2013;68:825–33. https://doi.org/10.1016/j.jaad.2012.10.041.

    Article  PubMed  Google Scholar 

  22. Moreau JF, Weissfeld JL, Ferris LK. Characteristics and survival of patients with invasive amelanotic melanoma in the USA. Melanoma Res. 2013;23:408–13. https://doi.org/10.1097/CMR.0b013e32836410fe.

    Article  PubMed  Google Scholar 

  23. Swetter SM, Ecker PM, Johnson DL, Harvell JD. Primary dermal melanoma: a distinct subtype of melanoma. Arch Dermatol. 2004;140:99–103. https://doi.org/10.1001/archderm.140.1.99.

    Article  PubMed  Google Scholar 

  24. Zettersten E, Shaikh L, Ramirez R, Kashani-Sabet M. Prognostic factors in primary cutaneous melanoma. Surg Clin North Am. 2003;83:61–75.

    Article  Google Scholar 

  25. Isaksson K, et al. Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts. J Surg Oncol. 2018;118:599–605. https://doi.org/10.1002/jso.25208.

    Article  PubMed  Google Scholar 

  26. Clark WH Jr, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893–904. https://doi.org/10.1093/jnci/81.24.1893.

    Article  PubMed  Google Scholar 

  27. Crowson AN, Magro CM, Mihm MC. Prognosticators of melanoma, the melanoma report, and the sentinel lymph node. Mod Pathol. 2006;19(Suppl 2):S71–87. https://doi.org/10.1038/modpathol.3800517.

    Article  PubMed  Google Scholar 

  28. Ladanyi A, et al. T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res. 2004;10:521–30.

    Article  CAS  Google Scholar 

  29. Conroy JM, et al. Analytical validation of a next-generation sequencing assay to monitor immune responses in solid tumors. J Mol Diagn. 2018;20:95–109. https://doi.org/10.1016/j.jmoldx.2017.10.001.

    Article  CAS  PubMed  Google Scholar 

  30. Xu X, et al. Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma. Clin Cancer Res. 2012;18:229–37. https://doi.org/10.1158/1078-0432.CCR-11-0490.

    Article  PubMed  Google Scholar 

  31. Barnhill RL, Lugassy C. Angiotropic malignant melanoma and extravascular migratory metastasis: description of 36 cases with emphasis on a new mechanism of tumor spread. Pathology. 2004;36:485–90. https://doi.org/10.1080/00313020412331282708.

    Article  PubMed  Google Scholar 

  32. Baer SC, Schultz D, Synnestvedt M, Elder DE. Desmoplasia and neurotropism. Prognostic variables in patients with stage I melanoma. Cancer. 1995;76:2242–7.

    Article  CAS  Google Scholar 

  33. Cymerman RM, et al. De novo vs nevus-associated melanomas: differences in associations with prognostic indicators and survival. J Natl Cancer Inst. 2016;108:djw121. https://doi.org/10.1093/jnci/djw121.

    Article  PubMed Central  Google Scholar 

  34. Balch CM, et al. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013;20:3961–8. https://doi.org/10.1245/s10434-013-3100-9.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Kretschmer L, et al. Age as a key factor influencing metastasizing patterns and disease-specific survival after sentinel lymph node biopsy for cutaneous melanoma. Int J Cancer. 2011;129:1435–42. https://doi.org/10.1002/ijc.25747.

    Article  CAS  PubMed  Google Scholar 

  36. Mervic L. Time course and pattern of metastasis of cutaneous melanoma differ between men and women. PLoS One. 2012;7:e32955. https://doi.org/10.1371/journal.pone.0032955.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Scoggins CR, et al. Gender-related differences in outcome for melanoma patients. Ann Surg. 2006;243:693–8; discussion 698–700. https://doi.org/10.1097/01.sla.0000216771.81362.6b.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Aizer AA, et al. Marital status and survival in patients with cancer. J Clin Oncol. 2013;31:3869–76. https://doi.org/10.1200/JCO.2013.49.6489.

    Article  PubMed  PubMed Central  Google Scholar 

  39. McLaughlin JM, Fisher JL, Paskett ED. Marital status and stage at diagnosis of cutaneous melanoma: results from the Surveillance Epidemiology and End Results (SEER) program, 1973–2006. Cancer. 2011;117:1984–93. https://doi.org/10.1002/cncr.25726.

    Article  PubMed  Google Scholar 

  40. Howard MD, et al. Anatomical location of primary melanoma: survival differences and sun exposure. J Am Acad Dermatol. 2019. https://doi.org/10.1016/j.jaad.2019.04.034.

  41. Garbe C, et al. Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer. 1995;75:2492–8.

    Article  CAS  Google Scholar 

  42. Bae JM, et al. Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2015;72:59–70. https://doi.org/10.1016/j.jaad.2014.09.029.

    Article  PubMed  Google Scholar 

  43. Weide B, et al. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer. 2012;107:422–8. https://doi.org/10.1038/bjc.2012.306.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Diem S, et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer. 2016;114:256–61. https://doi.org/10.1038/bjc.2015.467.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Sanmamed MF, et al. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. Clin Chim Acta. 2014;429:168–74. https://doi.org/10.1016/j.cca.2013.11.034.

    Article  CAS  PubMed  Google Scholar 

  46. Huang SK, Hoon DS. Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients. Mol Oncol. 2016;10:450–63. https://doi.org/10.1016/j.molonc.2015.12.008.

    Article  CAS  PubMed  Google Scholar 

  47. Alegre E, et al. Circulating melanoma exosomes as diagnostic and prognosis biomarkers. Clin Chim Acta. 2016;454:28–32. https://doi.org/10.1016/j.cca.2015.12.031.

    Article  CAS  PubMed  Google Scholar 

  48. Hyams DM, Cook RW, Buzaid AC. Identification of risk in cutaneous melanoma patients: prognostic and predictive markers. J Surg Oncol. 2019;119:175–86. https://doi.org/10.1002/jso.25319.

    Article  PubMed  Google Scholar 

  49. Gerami P, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015;21:175–83. https://doi.org/10.1158/1078-0432.CCR-13-3316.

    Article  CAS  PubMed  Google Scholar 

  50. Xing Y, et al. Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer. 2010;116:2234–41. https://doi.org/10.1002/cncr.24966.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Soong SJ, et al. Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database. Ann Surg Oncol. 2010;17:2006–14. https://doi.org/10.1245/s10434-010-1050-z.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

    Mohammed Almashali & Gyorgy Paragh

  2. Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

    Mohammed Almashali & Gyorgy Paragh

  3. Department of Dermatology, College of Medicine, Al Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia

    Mohammed Almashali

  4. Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK

    Robert Ellis

  5. Department of Dermatology, James Cook University Hospital, Middlesbrough, UK

    Robert Ellis

Authors
  1. Mohammed Almashali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Ellis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gyorgy Paragh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gyorgy Paragh .

Editor information

Editors and Affiliations

  1. Division of Dermatology, Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA

    Delphine J. Lee

  2. Cedars-Sinai Medical Center, The Angeles Clinic and Research Institute, Los Angeles, CA, USA

    Mark B. Faries

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Almashali, M., Ellis, R., Paragh, G. (2021). Melanoma Epidemiology, Staging and Prognostic Factors. In: Lee, D., Faries, M. (eds) Practical Manual for Dermatologic and Surgical Melanoma Management. Springer, Cham. https://doi.org/10.1007/978-3-030-27400-9_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-27400-9_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-27399-6

  • Online ISBN: 978-3-030-27400-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation